Facilitated By

San Antonio Medical Foundation

AN EARLY PHASE, MULTICENTER, OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOKINETICS OF ANTI PDd-L1 ANTIBODY (MPDL3280A) IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH PREVIOUSLY TREATED SOLID TUMORS

UT Health San Antonio

The UT Health San Antonio, with missions of teaching, research and healing, is one of the country’s leading health sciences universities.

Principal Investigator(s)
Langevin,Anne-Marie R
Funded by
SLOAN -KETTERING INSTITUTE FOR CANCER RE
Research Start Date
Status
Active
Clinical Care
Drug Discovery
Cancer